A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...

In heart failure, the heart can no longer supply the body with enough blood. The condition often develops over many years, ...

When CRISPR cuts a gene flanked by short, repeating DNA sequences, the cell’s repair machinery gets confused. It simply zips ...

The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...

What happened next may become the most important medical story of the decade. In just six months, a team at Children’s ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...

The company's strong cash position gives investors confidence in the gene-editing stock.

A treatment used a gene-editing tool to turn off a gene that prevents LDL cholesterol and triglycerides from being cleared ...

Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...